맞춤형 암 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global personalized cancer medicine market size is expected to reach USD 814.40 Billion in 2034 from USD 391.14 Billion in 2025, growing at a CAGR of 8.49% during 2026-2034.This market is growing as oncology increasingly focuses on tailoring treatment decisions to the biological characteristics of individual tumors and patients. Personalized cancer medicine uses information such as genetic alterations, molecular biomarkers, and other disease characteristics to guide the selection of suitable therapies. Growing recognition that patients with the same cancer type may respond differently to treatment is encouraging the adoption of individualized approaches. Advances in tumor profiling and targeted drug development are supporting more precise treatment strategies. Healthcare providers are increasingly using molecular information to identify potential treatment options and improve the alignment between therapies and disease characteristics.

Market growth is driven by progress in genomic sequencing, increasing availability of targeted therapies, and expanding research into immuno-oncology. Pharmaceutical companies are developing treatments directed at specific molecular pathways, while diagnostic laboratories are improving access to biomarker testing. Clinical trials increasingly incorporate molecular criteria to identify patients who may benefit from investigational therapies. Collaborations among biotechnology companies, research institutions, and healthcare providers are also accelerating the development of personalized treatment approaches. In addition, improvements in bioinformatics and clinical data analysis are helping researchers interpret complex biological information and identify new therapeutic opportunities.

The future prospects of this market will depend on continued advances in biomarker discovery, treatment development, and the integration of molecular testing into routine cancer care. Liquid biopsy technologies may support disease monitoring and the identification of emerging resistance mechanisms in selected clinical settings. Artificial intelligence could improve the analysis of genomic and clinical data, helping researchers identify patterns associated with treatment response. Combination therapies and personalized immunotherapy approaches may also expand treatment options. However, high testing and treatment costs, reimbursement limitations, tumor heterogeneity, and unequal access to specialized care remain significant challenges. Addressing these issues will be important for broader adoption.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

• Personalized Medicine Diagnostics
• Personalized Medicine Therapeutics

By End User

• Hospitals and clinics
• Others

COMPANIES PROFILED

• Roche, Thermo Fisher Scientific, Illumina, Foundation Medicine, Guardant Health, Exact Sciences, Tempus AI, Caris Life Sciences, Natera, NeoGenomics, QIAGEN, AstraZeneca, Novartis, Pfizer, Bristol Myers Squibb, Merck & Co., Johnson & Johnson, Amgen, Gilead Sciences, BioNTech

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PERSONALIZED CANCER MEDICINE MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Personalized Medicine Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Personalized Medicine Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PERSONALIZED CANCER MEDICINE MARKET: BY END USER 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End User
• 5.2. Hospitals and clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PERSONALIZED CANCER MEDICINE MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Product
  • 6.2.2 By End User
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Product
  • 6.3.2 By End User
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Spain
  • 6.3.8 Russia
  • 6.3.9 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Product
  • 6.4.2 By End User
  • 6.4.3 China
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 India
  • 6.4.7 Australia
  • 6.4.8 South East Asia
  • 6.4.9 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Product
  • 6.5.2 By End User
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Product
  • 6.6.2 By End User
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL PERSONALIZED CANCER MEDICINE INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Roche
  • 8.2.2 Thermo Fisher Scientific
  • 8.2.3 Illumina
  • 8.2.4 Foundation Medicine
  • 8.2.5 Guardant Health
  • 8.2.6 Exact Sciences
  • 8.2.7 Tempus AI
  • 8.2.8 Caris Life Sciences
  • 8.2.9 Natera
  • 8.2.10 NeoGenomics
  • 8.2.11 QIAGEN
  • 8.2.12 AstraZeneca
  • 8.2.13 Novartis
  • 8.2.14 Pfizer
  • 8.2.15 Bristol Myers Squibb
  • 8.2.16 Merck & Co
  • 8.2.17 Johnson & Johnson
  • 8.2.18 Amgen
  • 8.2.19 Gilead Sciences
  • 8.2.20 BioNTech